Protalix BioTherapeutics

Protalix BioTherapeutics

Protalix BioTherapeutics was incorporated in Israel in 1993 and went public on the NYSE American in 2007, a corporate lifespan that spans the full arc from platform conception to commercial-stage biotech. The founding team built the company around ProCellEx, an expression system that cultures genetically modified carrot cells in disposable bioreactors to produce therapeutic-grade proteins. That cell-culture choice turned into the firm's regulatory wedge: in May 2012 the FDA approved taliglucerase alfa (Elelyso) as the first plant-cell-derived biologic for Gaucher disease type 1, after a pivotal Phase III trial that enrolled treatment-naïve patients across 33 clinical sites globally. The firm's commercial footing rests squarely on Elelyso, licensed to Pfizer under a 2009 global agreement that covers all territories outside Israel and Brazil, where Protalix retains marketing rights. Pfizer books the bulk of product revenue and pays Protalix a tiered supply-share — a structure that kept Protalix's own operating costs lean even as the drug reached patients in the US, Israel, Brazil, and other jurisdictions. Beyond Gaucher disease, the pipeline runs on the same ProCellEx chassis: PRX-102 (pegunigalsidase alfa) targets Fabry disease and was the subject of a December 2023 complete response letter from the FDA, shifting the near-term calculus toward European and Israeli regulatory dossiers already under review. The firm has also explored plant-expressed antibodies, a tumor-targeted TNF-alpha fusion protein, and undisclosed early-stage candidates that leverage the platform's capacity for complex glycoproteins. Protalix operates from a manufacturing campus in Carmiel, Northern Israel, where the bioreactor suite can scale from clinical to commercial volumes without retrofitting. Dror Bashan assumed the CEO seat in 2019 after a tenure as VP Sales and Marketing at Teva, and CFO Eyal Rubin has steered the balance sheet through the post-Elelyso launch years. In March 2024 Protalix filed its annual report detailing cash reserves sufficient to fund operations into mid-2025, signaling a runway measured in months rather than years as it awaits fabry-disease regulatory outcomes. Structurally, Protalix is a product engine bolted to a global pharmaceutical distributor — a model that outsources the costly commercial infrastructure most mid-cap biotechs must build. The Pfizer deal covers regulatory submissions, marketing, and distribution for Elelyso in every market that matters commercially, leaving Protalix to operate essentially as a pure-play R&D-and-manufacturing entity. That split — Israeli R&D and manufacturing, American partner-led commercialization — makes it one of the few biotech platforms whose value proposition depends not on selling drugs itself but on proving its cell-expression technology can churn out novel biologics that large partners want to license.